Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hanmi Pharmaceutical Co. Ltd.

www.hanmipharm.com

Latest From Hanmi Pharmaceutical Co. Ltd.

Korean Pharma Highlights R&D Progress, 2020 Strategy At JPM

Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.

South Korea Business Strategies

Korea 2020 Outlook: Hopes Of Turnaround Amid Potential Deals, Biosimilar Launches, Biologics Law

After a year full of disappointing and unexpected events, the South Korean pharma sector is hoping for a turnaround in 2020, with expected biosimilar launches in global markets, progress in drug pipelines, large IPOs and implementation of a new law on cutting-edge biologics.

South Korea Clinical Trials

Key Words For Korean Pharma In 2010s: Novelty, Open Innovation, Global Markets

From being generics-focused to becoming innovators and leaders in biosimilars, Scrip takes a look at how the Korean pharma sector and environment have evolved over the past 10 years.

South Korea Business Strategies

Korea 2019 Review: Industry Spooked By Invossa Affair, Disappointing Trials But Hopes Intact

The South Korean pharma/biotech industry suffered a series of negative blows in 2019 but there were still notable achievements including major drug approvals and large-scale licensing deals.

South Korea Gene Therapy
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Gastrointestinal
  • Gynecological, Urological
  • Immune Disorders
  • Infectious & Viral Diseases
  • Metabolic Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Ophthalmic
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • South Korea
  • Parent & Subsidiaries
  • Hanmi Pharmaceutical Co. Ltd.
  • Senior Management
  • Se-Chang Kwon, PhD, Pres. & CEO
  • Contact Info
  • Hanmi Pharmaceutical Co. Ltd.
    Phone: 2 410 9114
    14, Wiryeseong-daero
    Songpa-gu
    Seoul,
    South Korea
UsernamePublicRestriction

Register